Duncan Bucknell

Please use the link to the oxford site to view this article

The US Court of Appeals for the Federal Circuit has now confirmed that a patent claim can be invalidated on what was previously considered to be a minor technical defect. (Basically,...

Like diamonds, trade marks last forever (provided that you manage them correctly). Thus, trade marks are a vital aspect of building and extending an IP monopoly in many fields, not least...

For the foreseeable future at least some confusion will remain about the scope of product by process claims in the US. On 22 June 2006 the US Court of Appeals for...

Despite litigation in at least ten jurisdictions across the world, Ranbaxy has so far been unable to obtain launch before patent expiry (~2011). (Further analysis below.) On 28 June 2006, the...

In preparation for expiry of the key blocking patent covering Zocor (Simvastatin), Merck has made two strategic but controversial moves in the USA to neutralize any advantage that generic first filers...

On 15 June 2006, the Full Federal Court of Australia handed down its judgment in Merck & Co Inc v Arrow Pharmaceuticals Limited [2006] FCAFC 91. Under Australian law, a patent...

On 5 May 2006 the Provincial High Court of Madrid handed down ruling 89/2006 in Merck Sharp & Dohme DE Espana S.A. v Bexal Farmaceutica, S.A. Take home Contrary to concern...

This is one for those in the pharmaceutical industry and an interest in the USA. It has potentially enormous implications for strategy in this industry in the US, and about zero...

On 19 May 2006, Mr Justice Pumfrey of the UK High Court (Patents Court) handed down his decision in Mayne Pharma v Debiopharm SA & Sanofi-Synthélabo [2006] EWHC 1123 (Pat). Take...